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Abstract
The thrombin-induced polymerisation of fibrinogen to form fibrin is well established as a late
stage of blood clotting. It is known that Parkinson’s Disease (PD) is accompanied by dysre-
gulation in blood clotting, but it is less widely known as a coagulopathy. In recent work, we
showed that the presence of tiny amounts of bacterial lipopolysaccharide (LPS) in healthy indi-
viduals could cause clots to adopt an amyloid form, and this could be observed via scanning
electron microscopy (SEM) or via the fluorescence of thioflavin-T. This could be prevented by
the prior addition of lipopolysaccharide-binding protein (LBP). We had also observed by SEM
this unusual clotting in the blood of patients with Parkinson’s Disease. We hypothesised, and
here show, that this too can be prevented by LBP in the context of PD. This adds further evi-
dence implicating inflammatory microbial cell wall products as an accompaniment to the dis-
ease, and may be part of its aetiology. This may lead to novel treatment strategies in PD
designed to target microbes and their products.
Introduction
It is widely recognized that that many chronic, inflammatory diseases are accompanied by
insoluble amyloid fibril formation [1–7]. Parkinson’s Disease (PD) is one such condition, and
is accompanied by amyloid forms of α-synuclein in the substantia nigra pars compacta [8–13].
To this end, systems biology approaches [14–18] have made considerable headway in account-
ing for the known “Parkinson’s” genes in biochemical terms, with the additional recognition
that dysregulated cytokines, oxidative stress and particularly iron dysregulation are also major
contributors to disease progression [19–31].
It is rather less widely recognized that PD may also be accompanied by changes in the nor-
mal clotting of blood, i.e. it may be a coagulopathy [32–35], albeit the last of these papers sug-
gested that the changes were more in the complement than the coagulation cascade. Indeed,
PD in treated patients has been observed to be accompanied by changes in prothrombin time
and D-dimer formation (Sato et al., 2003), as well as by eryptosis [35]. Focusing on the termi-
nal stages of the coagulation cascade, thrombin removes two fibrinopeptides from fibrinogen,
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thereby allowing the fibrinogen to self-assemble into insoluble fibrin via a ‘knobs and holes’
mechanism (e.g. [36–40]). There are not otherwise considered to be any major changes in sec-
ondary structure of the protein [36, 41–43]. A final crosslinking step catalyzed by Factor XIII,
after it too has been activated by thrombin, [44] increases the stability of the clot.
In healthy individuals, the addition of thrombin to platelet poor plasma (PPP) causes the
fibres forming the subsequent clot to appear as loosely collected netlike structures (comparable
to a plate of noodles or spaghetti) under the scanning electron microscope [45–49]. However,
we and others have observed that fibre diameter and morphology change markedly in a variety
of vascular and inflammatory diseases, typically producing ‘dense matter deposits’ (e.g. [46,
50–59]).
Even though, as mentioned, there are usually no major changes in the secondary structure
of the fibre protein during polymerization, it can undergo structural changes under certain
conditions. Although fibrinogen is not considered to be amyloidogenic, nor is fibrin seen as an
amyloid protein, it can nonetheless become so in the presence of a rare mutation in the fibrin-
ogen a chain [60–63]), or by extreme mechanical stretching [64–66]. A very specific feature of
amyloid proteins is the formation of a cross-β-sheet structure, perpendicular to the fibres with
a characteristic spacing (observable in X-ray reflections) of 4.7–4.8Å (e.g. [4, 7, 67, 68]). In con-
trast to normal structures, thioflavin T (ThT) binds strongly to them, and fluoresces intensely
at 480–520 nm when excited at ~440 nm (e.g. [69–74]). Indeed, following many observations
in the SEM of anomalous blood clotting (e.g. [27, 48, 49, 58, 59, 75–77]), we have recently
established [77, 78] that this anomalous clotting is in fact amyloid in nature.
Previously in our laboratory, we have shown that fibrin amyloid formation occurred in the
presence of tiny amounts of bacterial lipopolysaccharide (LPS) (0.2 ngL-1; 1 molecule per 108
fibrinogen molecules), but was abolished when this was added together with a two-fold stoi-
chiometric excess of human LBP (lipopolysaccharide binding protein) [77]. We have particu-
larly emphasised that dormant bacteria are widespread in nature [79–83], and we have argued
strongly for a role for dormant bacteria in the aetiology of such diseases [84–91]. Indeed, re-
cent work in mice lends strong support to the view that the gut microbiome can play a major
role in the aetiology of PD [11]. Iron is also capable of catalysing anomalous blood clotting [75,
76], and as mentioned previously, there are strong indications for both iron dysregulation [16,
21, 25–27, 92–97] and coagulopathies [58] in Parkinson’s Disease.
The purpose of the present paper was thus to study whether (and to what extent) fibrin-type
amyloid in blood varies between suitably matched controls and individuals with Parkinson’s
Disease. In addition, we wished to investigate whether LBP affected this in any way, to a poten-
tially therapeutic effect. It became clear that the answers are in the affirmative in both cases.
Materials and methods
Ethical statement
Ethical clearance was obtained from the Health Sciences Ethical Committee of the University of
Pretoria and written informed consent was obtained from each of the patients, as well as from
control donors (ethical number: 80/2013 and reapproved 2015) (available on request). Exclu-
sion criteria for the PD patients were conditions such as asthma, human immunodeficiency
virus (HIV) or tuberculosis, and risk factors associated with metabolic syndrome, smoking, and
(if female) being on contraceptive or hormone replacement treatment. Exclusion criteria for the
healthy population were known inflammatory conditions such as asthma, human immunodefi-
ciency virus (HIV) or tuberculosis, and risk factors associated with metabolic syndrome, smok-
ing, and if female, being on contraceptive or hormone replacement treatment. This population
did not take any anti-inflammatory medication. Whole blood of all participants was obtained in
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citrate tubes and platelet poor plasma (PPP) was used for confocal and SEM experiments. The
methods were carried out in accordance with the approved guidelines. Blood was collected and
methods were carried out in accordance with the relevant guidelines of the ethics committee.
We adhered strictly to the Declaration of Helsinki.
Sample population
In this study, 19 healthy, age-controlled individuals, of whom 9 were spouses of some of the
Parkinson’s Disease (PD) individuals, and 26 individuals diagnosed with PD, were included.
The PD patients were diagnosed by a Neurologist and the Unified Parkinson’s Disease Rating
Scale (UPDRS) was used in this diagnosis. On the day of blood collection, the Hoehn and Yahr
scale was used by a clinician to rate the relative level of the PD disability. Margaret M. Hoehn
and Melvin D. Yahr developed the Hoehn and Yahr scale to scale practically the severity of PD
at the time of treatment, and thereby determine whether the medication or treatment that is
used influences the rate of the progression of the disease [98]. Many studies thereafter have
used this method in scaling the severity of movement disorders [99–103].
LPS-binding protein
A final LPS-binding protein (LBP) exposure concentration of 2 ngL-1 LBP was used [77]. LBP
was purchased from Sigma (recombinant product SRP6033;>95% pure). Previously we re-
ported that LBP added to healthy plasma does not change or affect the structure of healthy fibrin
viewed with scanning electron microscopy (SEM) [104]. We also previously showed with confo-
cal microscopy that healthy PPP with added LBP (after addition of thrombin) showed little
change in fluorescent (amyloid) signal [77].
Airyscan and scanning electron microscopy
PPP was prepared from whole blood collected in citrated tubes, from both healthy and PD indi-
viduals. For Airyscan preparation, we added Thioflavin T (ThT) at a final concentration of
5 μM to 200 μL of various prepared PPP samples and incubated it (protected from light) for one
minute. This step was followed with the addition of thrombin, added in the ratio 1:2 to create
extensive fibrin networks. A coverslip was placed over the prepared clot, and viewed immedi-
ately using a Zeiss LSM 510 META confocal microscope with a Plan-Apochromat 63× and
100×/1.4 Oil DIC objective and super-resolution (Airyscan) capabilities. The Airyscan detector
increases the resolution by a factor of 1.7, achieving super-resolution of 140 nm. Excitation was
at 488 nm and emitted light was measured at 505–550 nm. In addition, PPP from PD individu-
als was incubated with LBP (final concentration 2 ngL-1) for 10 minutes, followed by ThT and
clot preparation as for the healthy and naïve PD PPP. Clots were also prepared for SEM analysis,
but after addition of thrombin, clots were washed, fixed in 4% formaldehyde and prepared for
SEM according to known SEM preparation methods (e.g. Pretorius et al. 2013b). Samples were
viewed using a Zeiss cross beam electron microscope to study fibrin fibres.
Statistical analysis and data sharing
We used a One-Way ANOVA with Holm-Sˇı´da´k Multiple Comparison’s Test for the SEM anal-
ysis (controls vs. PD vs. PD with added LBP), comparing the mean of each column with the
mean of every other column (GraphPad 7). The paired t-test analysis was done for the Airyscan
analysis (PD with and without LBP). For each picture, we obtained the histogram of intensities
(8-bit scale) using the histogram function of ImageJ. From this, we calculated the coefficient of
variation (CV, as standard deviation/mean) (see [104] for detailed methodology). The
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experiments were done blinded and data capturing and analysis of micrographs were per-
formed by different co-authors.
All relevant data (Excel data files, lab SOPs, and the raw data graphpad stats file) to replicate
the study’s findings are available from figshare: https://doi.org/10.6084/m9.figshare.5844738.
Full confocal and electron microscopy micrographs files are available from the corresponding
author or at the following link: https://1drv.ms/f/s!AgoCOmY3bkKHmWY8VijKiQ-8_5RY."
Results
Table 1 shows demographics for the healthy and the PD groups. Medication usage may influ-
ence the hematological system; however, previously we reviewed literature on PD medication
interactions with the haematological system, and no significant interactions were previously
reported (see [35] and Table 1). The median of the Hoehn and Yahr scale for the PD individu-
als were 2.5 (±0.43); suggesting that mostly, individuals participating in this study had mild
bilateral PD symptoms at date of blood collection. Airyscan and SEM results are shown in Figs
1–4, for the healthy and PD individuals.
Scanning electron microscopy of PPP clots
Fig 1A and 1B show how fibrin clots created from healthy PPP look like under a 10 000×
machine magnification. Fibres have a spaghetti-like appearance, where individual fibres are
visible. On the other hand, fibrin clots created from PPP of PD individuals all have a typical
matted appearance, where individual fibres are entwined into a matted mass (see Fig 1C),
indicative of hypercoagulation.
We recently suggested that this changed fibrin protein structure in inflammatory condi-
tions like T2D, rheumatoid arthritis and others, are due to β-sheet-rich areas forming in
the presence of both upregulated inflammatory markers, and particularly the presence or
LPS [77]. We also showed that LPS added to healthy PPP created clots lead to hypercoagu-
lation, and that the addition of LBP could reverse this pathological fibrin structure [77].
We additionally demonstrated that the pathological fibrin structure of T2D could be re-
versed with the addition of LBP (Pretorius et al., 2017a). Overall, we suggested that LBP
protects the fibres from LPS damage by binding to LPS and, therefore, that LBP could
decreaseβ-sheet-rich areas in T2D plasma.
Here we added LBP to PPP from PD individuals (see Fig 1D). We could show that in all our
PD samples that a structural reversion to a state similar to clots created from healthy PPP
could be obtained.
Table 1. Demographics and medication usage of Parkinson’s individuals.
HEALTHY INDIVIDUALS (N = 19)
Gender Age
Median; STD; % 74% F; 26% M All: 67.0 (±9.8) M: 67.0 (± 8.5) F: 67.0 (±10.5)
PARKINSON’S DISEASE INDIVIDUALS (Hoehn and Yahr scale 2.5 (±0.43) (N = 26)
Median; STD; % 35% F: 65% M All: 70 (±4.1) M: 70 (± 4.1) F: 71 (±4.2)
PD MEDICATION USAGE
[Ropinirole (Requip1), SINEMET1 (carbidopa-levodopa), Comtan1 (entacapone), Pramipexole, Pexola1,
Rasagiline, Azilect1,Stalevo1 (carbidopa, levodopa, and entacapone), Madopar1 (levodopa + benserazide),
Carbilev1 (carbidopa + levodopa) Amantadine].
https://doi.org/10.1371/journal.pone.0192121.t001
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Airyscan super-resolution microscopy of clots created from PPP
Previously we have noted that in healthy PPP, in the presence of ThT, little fluorescence was
present, with only occasional very small patches of fluorescence [77, 78]. This might be because
in all individuals (even if they are perceived to be healthy) there might be minor areas of mis-
folding of fibrin(ogen). We have also previously shown that when LPS had been incubated in
healthy PPP, prior to the addition of thrombin, fluorescence was greatly enhanced, suggesting
increased binding of ThT to β-sheet-rich areas on the fibrin(ogen) [77, 78]. From these results,
we concluded that LPS binding causes the fibrinogen to polymerise into a form with a greatly
increased amount of β-sheet (in the presence of thrombin), reflecting amyloid formation. This
causes a strong fluorescence observable (when excited ca 440 nm) in the presence of ThT (see
e.g. [70, 71]). In this paper, we also show β-sheet-rich areas in clots created from PPP of PD
individuals (Fig 2).
Both Airyscan and SEM techniques are typically used only as qualitative methods. However,
due to the increased fluorescence in clots prepared from PPP of PD, and also the more uniform
Fig 1. A and B) Clot structure from two healthy individuals, imaged in an SEM and showing a ‘normal’ ‘spaghetti’ or ‘noodle’ type of structure. All clots
were created by adding thrombin to PPP. C) SEM micrographs of PPP from a Parkinson’s disease individuals with added thrombin, showing a ‘dense
matted deposit’; D) PPP from same individual, but exposed to 2ng.L-1 LPS-binding protein followed by addition of thrombin; now showing a structure
similar to that of healthy controls.
https://doi.org/10.1371/journal.pone.0192121.g001
Amyloid state of fibrin in Parkinson’s disease
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and matted clot structure shown in SEM analysis of clots prepared from PD PPP, the variance
between light and dark pixels are much less than seen in clots prepared from healthy PPP. We
therefore propose using the coefficient of variation (CV) as our metric to quantify and discrimi-
nate between clots form healthy PPP and clots from PD PPP. We used ImageJ to calculate the
mean and standard deviation of the intensity of the pixels in the images of the clot, using the his-
togram function, followed by the calculation of the coefficient of variation (i.e. SD/mean) of the
intensity of the clot structure. Fig 3 shows boxplots of our results and Fig 4A–4D show examples
of representative histograms of the 8-bit intensity for a typical SEM and confocal clot with and
without LBP of a patient with PD (for the statistical analysis of results see Table 2).
Although LBP added to plasma from PD patients improved the structure of the fibrin(ogen)
(see Fig 3, Airyscan boxplot), the PD with added LBP results are still statistically different from
the control donors. LBP therefore does not allow the fibrin(ogen) to resemble fully that found
in healthy individuals. We previously found in type 2 diabetes (T2D) [104] that when LBP is
added to plasma from T2D, it did resemble that of healthy plasma.
We did not, in this paper, repeat Airyscan analysis with clots created with healthy PPP.
However, we previously reported that in healthy individuals, little amyloid fluorescence is
present when viewing clots with the added fluorescent marker, ThT [104–106].
Discussion
Although we have observed anomalies in the kinds of fibrin fibres produced in the plasma of
patients with various inflammatory diseases (e.g. [46, 49, 59, 75, 76, 78, 107–109]), this is the
first time that we have observed fibrin amyloid in Parkinson’s Disease, as assessed by ThT
Fig 2. A): Airyscan micrographs of PPP with added thrombin to form extensive fibrin fibres from an individual with Parkinson’s disease (PD);
B) PPP from the same individual, but exposed to 2ng.L-1 LPS-binding protein followed by addition of thrombin. Thioflavin T (ThT) (5 μM)
was added before thrombin. Micrographs were taken with a Zeiss LSM 510 META confocal microscope with a Plan-Apochromat 63x/1.4 Oil
DIC objective. LBP dramatically reduced the fluorescence seen in samples from patients with PD. Gain settings were kept the same during all
data capturing and not changed for statistical analysis, but brightness and contrast was slightly adjusted for fig preparation.
https://doi.org/10.1371/journal.pone.0192121.g002
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staining, and its sensitivity (and that of fibres observed in the SEM) to LBP. While fibrin and
α-synuclein can coaggregate [110], it is especially notable that the thrombin-dependence and
SEM fibre sizes imply that the fibres we observe are essentially all made of fibrin. Although
α-synuclein fibre formation in the substantia nigra is characteristic of PD, it can also occur
extracellularly, and its removal may be of therapeutic benefit [111, 112]. The production may
be driven by intestinal LPS [113], while gut microbiota-derived short-chain fatty acids may
also have a role [11]. Because the addition of LBP to plasma of PD individuals improves the
pathological state of the fibrin(ogen), we take it as indirect evidence that LPS has a role in this
disease. So far as is known, the only action of LBP, and certainly at these concentrations, is to
remove tiny amounts of LPS and related molecules, and only LPS has been shown (by us) to
have this massive substoichiometric effect in affecting clotting [77, 104, 105]. Thus, targeting
intestinal LPS possibly to not only reduce the production of extracellular α-synuclein, but also
to target pathological clotting in PD, is therefore potentially a sensible treatment strategy to
investigate further. The discovery that the addition of LBP to plasma influences the structure
of fibrin(ogen), furthermore lends credence to the possible role of LPS in the aetiology of PD.
In terms of treatment [114, 115], we have previously discussed the potential role of iron
chelators, both to stop the Fenton reaction [25, 26] and to inhibit microbial proliferation (e.g.
[84–86, 91]), and iron chelators can definitely also inhibit the formation of dense matted
(fibrin(ogen)) deposits (which is a hallmark of coagulopathies) (e.g. [27, 49, 58, 76, 116, 117]).
We have also previously reported that the red blood cells (RBCs) of PD individuals are erypto-
tic [35], mainly due to the presence of circulating cytokines and increased oxidative stress
[118, 119]. The possible removal of amyloid by LBP may also affect other cells of the
Fig 3. Boxplots of the distribution of the coefficients of variation in the pixel intensities of the SEM and Airyscan clot images.
https://doi.org/10.1371/journal.pone.0192121.g003
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haematological system, e.g. RBCs. It is now clear that treatment options worth exploring also
include anticoagulants; as yet, however, the evidence for any effect of heparin is still awaited,
due to Randomised Control Trials not having been done [120].
Concluding remarks
We show here that (1) LBP is a potential treatment for PD-associated coagulopathies and
(2) that the normalizing effect of LBP on fibrin(ogen) structure, strongly (albeit indirectly)
points to the possibly important role of LPS in the aetiology of PD. Overall, the remarkable
reversal of amyloid fibrin formation by LBP addition to the plasma of Parkinson’s Disease
patients firstly present a novel strategy for treating PD-associated- coagulopathies and
Fig 4. A and B) Representative histograms of the 8-bit intensity for a representative SEM clot from PPP of an individual with Parkinson’s disease and after addition of
LBP, respectively. C and D) Representative histograms of the 8-bit intensity for a typical Airyscan clot from PPP of an individual with Parkinson’s disease and after
addition of LBP, respectively.
https://doi.org/10.1371/journal.pone.0192121.g004
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secondly implies strongly that LPS is naturally pre-existing in said plasma. Although almost
all the LPS is bound to plasma proteins under normal conditions [86], including presum-
ably to fibrinogen but in concentrations that are consequently hard to determine [86], it
is known from experiments where LPS was added exogenously, that LBP molecules can
inhibit the LPS-induced formation of the amyloid form of fibrin when thrombin is present
[77]. Any endotoxin content of the PPP, ThT, LBP and thrombin is not known; however,
the fact that the effect was fully reversed by LBP shows that any such endotoxin content
must be negligible and/or irrelevant. So far as is known, the only action of LBP, and cer-
tainly at these concentrations, is to remove tiny amounts of LPS and related molecules, and
only LPS has been shown (by us) to have this massive substoichiometric effect in affecting
clotting. Consequently, the present work lends support to the idea (and evidence [121, 122])
that a dormant blood and tissue microbiome, capable of shedding LPS, is at least part of the
aetiology of Parkinson’s Disease.
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